Download PDF
Neuropediatrics
DOI: 10.1055/a-2288-6383
Original Article

Reliability and Validity of the Turkish Translation of the PedsQL™ 3.0 Neuromuscular Module for 2-to 4-Year-Olds in Spinal Muscular Atrophy

Seval Kutlutürk Yıkılmaz 
1   Department of Physiotherapy and Rehabilitation, Faculty of Hamidiye Health Sciences, University of Health Sciences, Istanbul, Turkey
,
Müberra Tanrıverdi 
2   Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Bezmialem Vakıf University, İstanbul, Turkey
,
Sedat Öktem
3   Department of Pediatric Pulmonary Diseases, Faculty of Medicine, Istanbul Medipol University, İstanbul, Turkey
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Background The Pediatric Quality of Life Inventory™ (PedsQL™) Neuromuscular Module (PedsQL™ 3.0 NM) evaluates the health-related quality of life in children who are affected by neuromuscular diseases. This study's aim is to assess the adaptation of the PedsQL™ 3.0 NM Turkish version (PedsQL™ 3.0 NM-TR) for 2- to 4-year-olds in spinal muscular atrophy (SMA).

Methods The procedure of translating the PedsQL™ 3.0 NM into Turkish was conducted in accordance with the translation methodology outlined by the PedsQL™ measurement model. The PedsQL™ 3.0 NM-TR was administered to 54 parents of children with SMA aged 2 to 4 years. The test–retest reliability and intraclass correlation coefficient (ICC) were measured for reliability analysis. Cronbach's α coefficient and item score correlations were calculated for internal consistency. Concurrent construct validity was evaluated by Pearson correlations between the outcomes of the PedsQL™ 4.0 Generic Core Scale (PedsQL™ 4.0 GCS) and the PedsQL™ 3.0 NM.

Results The PedsQL™ 3.0 NM-TR total score shows excellent reliability. The Cronbach's α values for the PedsQL™ 3.0 NM ranged between 0.871 and 0.906, while those for the PedsQL™ 4.0 GCS ranged between 0.843 and 0.897. Test–retest ICC values for the PedsQL™ 3.0 NM-TR ranged between 0.812 and 0.917, and for the PedsQL™ 4.0 GCS ranged between 0.773 and 0.899. The relationship between the PedsQL™ 3.0 NM-TR and the subscores of the PedsQL™ 4.0 GCS demonstrated a range of correlations from excellent to fair, indicating the interplay between two scales.

Conclusion This study established the PedsQL™ 3.0 NM-TR as reliable, valid, and feasible for use in children aged 2 to 4 years with SMA.

Keywords

child - Turkish - neuromuscular diseases - spinal muscular atrophy - quality of life

Ethics Approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Istanbul Medipol University (Date: January 12, 2022/No: E-10840098-772.02-213).


Authors' Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by S.K.Y., M.T., and S.Ö. The first draft of the manuscript was written by S.K.Y. and M.T. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.


Conceptualization: S.K.Y., M.T., S.Ö. Methodology: S.K.Y., M.T. Formal analysis and investigation: S.K.Y., M.T. Writing—original draft preparation: S.K.Y., M.T., S.Ö. Writing—review and editing: S.K.Y., M.T., S.Ö. Funding acquisition: S.K.Y., M.T., S.Ö. Resources: S.K.Y., M.T., S.Ö. Supervision: S.Ö.




Publication History

Received: 19 December 2023

Accepted: 14 March 2024

Accepted Manuscript online:
15 March 2024

Article published online:
08 April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Iolascon G, Paoletta M, Liguori S, Curci C, Moretti A. Neuromuscular diseases and bone. Front Endocrinol (Lausanne) 2019; 10: 794
    Google Scholar
  • 2 Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008; 371 (9630) 2120-2133
    Google Scholar
  • 3 Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol 2007; 22 (08) 946-951
    Google Scholar
  • 4 Mercuri E, Finkel RS, Muntoni F. et al; SMA Care Group. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 2018; 28 (02) 103-115
    Google Scholar
  • 5 Lin CW, Kalb SJ, Yeh WS. Delay in diagnosis of spinal muscular atrophy: a systematic literature review. Pediatr Neurol 2015; 53 (04) 293-300
    Google Scholar
  • 6 Vaidya S, Boes S. Measuring quality of life in children with spinal muscular atrophy: a systematic literature review. Qual Life Res 2018; 27 (12) 3087-3094
    Google Scholar
  • 7 Wong BL, Hynan LS, Iannaccone ST. American Spinal Muscular Atrophy Randomized Trials (AmSMART) Group. A randomized, placebo-controlled trial of creatine in children with spinal muscular atrophy. J Clin Neuromuscul Dis 2007; 8 (03) 101-110
    Google Scholar
  • 8 Iannaccone ST, Hynan LS. American Spinal Muscular Atrophy Randomized Trials (AmSMART) Group. Reliability of 4 outcome measures in pediatric spinal muscular atrophy. Arch Neurol 2003; 60 (08) 1130-1136
    Google Scholar
  • 9 Iannaccone ST. American Spinal Muscular Atrophy Randomized Trials (AmSMART) Group. Outcome measures for pediatric spinal muscular atrophy. Arch Neurol 2002; 59 (09) 1445-1450
    Google Scholar
  • 10 Iannaccone ST, Hynan LS, Morton A, Buchanan R, Limbers CA, Varni JW. AmSMART Group. The PedsQL in pediatric patients with Spinal Muscular Atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Neuromuscular Module. Neuromuscul Disord 2009; 19 (12) 805-812
    Google Scholar
  • 11 World Health Organization. Constitution of the World Health Organization Basic Document. Geneva, Switzerland:: World Health Organization.; 1948
    Google Scholar
  • 12 Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 1999; 37 (02) 126-139
    Google Scholar
  • 13 Rajmil L, Herdman M, Fernandez de Sanmamed MJ. et al; Kidscreen Group. Generic health-related quality of life instruments in children and adolescents: a qualitative analysis of content. J Adolesc Health 2004; 34 (01) 37-45
    Google Scholar
  • 14 Varni JW, Limbers CA, Burwinkle TM. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes 2007; 5: 43
    Google Scholar
  • 15 Uneri OS, Agaoglu B, Coskun A, Memik NC. Validity and reliability of Pediatric Quality of Life Inventory for 2- to 4-year-old and 5- to 7-year-old Turkish children. Qual Life Res 2008; 17 (02) 307-315
    Google Scholar
  • 16 Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 2000; 25 (24) 3186-3191
    Google Scholar
  • 17 Das S, Mitra K, Mandal M. Sample size calculation: Basic principles. Indian J Anaesth 2016; 60 (09) 652-656
    Google Scholar
  • 18 Sağlık TC. Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü Araştırma GtvSlTDeDBkı. Spinal Musküler Atrofi Klinik Protokolü. 2022
    Google Scholar
  • 19 Thongsing A, Suksangkarn Y, Sanmaneechai O. Reliability and validity of the Thai pediatric quality of life inventory™ 3.0 neuromuscular module. Health Qual Life Outcomes 2020; 18 (01) 243
    Google Scholar
  • 20 Taber KS. The use of Cronbach's alpha when developing and reporting research ınstruments in science education. Res Sci Educ 2018; 48: 1273-1296
    Google Scholar
  • 21 Fleiss JL. Reliability of measurement. In: The Design and Analysis of Clinical Experiments. New York,: Wiley; 1986: 1-32
    Google Scholar
  • 22 Mozzoni J, Gómez S, Monges MS. et al. Validation of the Pediatric Quality of Life Inventory™, Neuromuscular Module, version 3.0 in Spanish for Argentina. Arch Argent Pediatr 2021; 119 (04) e286-e297
    Google Scholar
  • 23 Wiwaha G, Sari DM, Biben V, Sunjaya DK, Hilmanto D. Translation and validation of Indonesian version of Pediatric Quality of Life Inventory™ (PedsQL™) Neuromuscular Module. Health Qual Life Outcomes 2022; 20 (01) 33
    Google Scholar
  • 24 Kocova H, Dvorackova O, Vondracek P, Haberlova J. Health-related quality of life in children and adolescents with spinal muscular atrophy in the Czech Republic. Pediatr Neurol 2014; 50 (06) 591-594
    Google Scholar
  • 25 Yüksel D, Haliloğlu G, Ergün M. et al. Spinal Musküler Atrofi Taşıyıcı Tarama Programı Saha Rehberi. 2021. Available at: https://hsgm.saglik.gov.tr/depo/birimler/cocuk-ergen-sagligi-db/Programlar/EO_SMA_TASIYICI_TARAMA_PROGRAMI_SAHA_REHBERI.pdf Accessed April 1, 2024
    Google Scholar
  • 26 Sawada T, Kido J, Yae Y. et al. Gene therapy for spinal muscular atrophy is considerably effective when administered as early as possible after birth. Mol Genet Metab Rep 2023; 35: 100973 . Accessed at: https://doi.org/10.1016/j.ymgmr.2023.100973
    Google Scholar